DexCom, Inc. (NASDAQ:DXCM) – Research analysts at Northcoast Research reduced their Q2 2017 earnings per share estimates for DexCom in a report released on Wednesday. Northcoast Research analyst E. Snyder now anticipates that the medical device company will post earnings of ($0.21) per share for the quarter, down from their prior forecast of ($0.18). Northcoast Research also issued estimates for DexCom’s Q3 2017 earnings at ($0.10) EPS, Q4 2017 earnings at $0.05 EPS and FY2017 earnings at ($0.74) EPS.

DXCM has been the subject of several other reports. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of DexCom in a research note on Thursday, April 13th. Canaccord Genuity reaffirmed a “buy” rating and issued a $90.00 price objective on shares of DexCom in a research note on Wednesday, June 7th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $78.00 price objective on shares of DexCom in a research note on Monday, May 22nd. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $90.00 price objective on shares of DexCom in a research note on Friday, July 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company. DexCom currently has a consensus rating of “Buy” and an average price target of $89.47.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/07/28/northcoast-research-equities-analysts-cut-earnings-estimates-for-dexcom-inc-dxcm.html.

Shares of DexCom (NASDAQ:DXCM) opened at 66.49 on Friday. The firm’s market capitalization is $5.74 billion. The stock has a 50 day moving average price of $72.71 and a 200-day moving average price of $75.68. DexCom has a 52 week low of $57.68 and a 52 week high of $96.38.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, May 2nd. The medical device company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.06. DexCom had a negative return on equity of 32.94% and a negative net margin of 14.70%. The company had revenue of $142.30 million for the quarter, compared to analyst estimates of $143.94 million.

Hedge funds have recently made changes to their positions in the company. Independent Portfolio Consultants Inc. raised its stake in shares of DexCom by 0.4% in the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after buying an additional 9 shares during the last quarter. Bbva Compass Bancshares Inc. raised its stake in shares of DexCom by 1.9% in the second quarter. Bbva Compass Bancshares Inc. now owns 3,670 shares of the medical device company’s stock worth $268,000 after buying an additional 69 shares during the last quarter. Mn Services Vermogensbeheer B.V. raised its stake in shares of DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock worth $179,000 after buying an additional 83 shares during the last quarter. Public Employees Retirement Association of Colorado raised its stake in shares of DexCom by 0.4% in the second quarter. Public Employees Retirement Association of Colorado now owns 18,613 shares of the medical device company’s stock worth $1,362,000 after buying an additional 83 shares during the last quarter. Finally, King Luther Capital Management Corp raised its stake in shares of DexCom by 0.7% in the first quarter. King Luther Capital Management Corp now owns 12,105 shares of the medical device company’s stock worth $1,026,000 after buying an additional 90 shares during the last quarter.

In other DexCom news, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $78.19, for a total value of $113,375.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Richard Doubleday sold 3,182 shares of the firm’s stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $68.29, for a total value of $217,298.78. Following the completion of the transaction, the executive vice president now directly owns 72,395 shares in the company, valued at $4,943,854.55. The disclosure for this sale can be found here. Insiders sold a total of 36,331 shares of company stock worth $2,548,619 over the last ninety days. Corporate insiders own 1.70% of the company’s stock.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.